The clinical implication of CTLA-4 expression in tumors or immune cells in the tumor microenvironment is still controversial, and the potential for CTLA-4 as prognostic and therapeutic marker has been complicated by differences in study population, methods and histological tumor types [53–54]. Here, CTLA4 is linked to neoplasm.